公开(公告)号：US09585945B2

公开(公告)日：2017-03-07

申请号：US14948095

申请日：2015-11-20

Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Mi-La Cho ,  Hyang-Suk Rhim ,  Seon-Yeong Lee ,  Yeong-Mi Mun ,  Hye-Jin Son ,  Eun-Ji Yang ,  Eun-Kyung Kim

IPC: C12N9/12 ,  A61K48/00 ,  A61K38/45

CPC classification number: A61K38/45 ,  A61K48/005 ,  C12N9/12 ,  C12Y207/11001

Abstract: The present invention relates to a composition for preventing or treating an autoimmune disease comprising, as an active ingredient, PINK1 protein or polynucleotide encoding the same. The PINK1 protein according to the present invention inhibits the activity of Th17, promotes the activity of a regulatory T cell (Treg), and increases autophagy in Treg cells, thereby controlling excessive immune responses. Therefore, the PINK1 protein can be effectively used as a pharmaceutical composition or an immunosuppressant, which is capable of preventing or treating an autoimmune disease, such as arthritis, and the like, caused by dysregulation of various kinds of immune responses.

Abstract translation: 本发明涉及用于预防或治疗自身免疫疾病的组合物，其包含作为活性成分的PINK1蛋白或编码该组合物的多核苷酸。 根据本发明的PINK1蛋白抑制Th17的活性，促进调节性T细胞（Treg）的活性，并增加Treg细胞中的自噬，由此控制过度的免疫应答。 因此，可以将PINK1蛋白质有效地用作药物组合物或免疫抑制剂，其能够预防或治疗由各种免疫反应失调引起的自身免疫疾病如关节炎等。

公开(公告)号：US20160114007A1

公开(公告)日：2016-04-28

申请号：US14948095

申请日：2015-11-20

Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Mi-La Cho ,  Hyang-Suk Rhim ,  Seon-Yeong Lee ,  Yeong-Mi Mun ,  Hye-Jin Son ,  Eun-Ji Yang ,  Eun-Kyung Kim

IPC: A61K38/45

CPC classification number: A61K38/45 ,  A61K48/005 ,  C12N9/12 ,  C12Y207/11001

Abstract: The present invention relates to a composition for preventing or treating an autoimmune disease comprising, as an active ingredient, PINK1 protein or polynucleotide encoding the same. The PINK1 protein according to the present invention inhibits the activity of Th17, promotes the activity of a regulatory T cell (Treg), and increases autophagy in Treg cells, thereby controlling excessive immune responses. Therefore, the PINK1 protein can be effectively used as a pharmaceutical composition or an immunosuppressant, which is capable of preventing or treating an autoimmune disease, such as arthritis, and the like, caused by dysregulation of various kinds of immune responses.

Abstract translation: 本发明涉及用于预防或治疗自身免疫疾病的组合物，其包含作为活性成分的PINK1蛋白或编码该组合物的多核苷酸。 根据本发明的PINK1蛋白抑制Th17的活性，促进调节性T细胞（Treg）的活性，并增加Treg细胞中的自噬，从而控制过度的免疫应答。 因此，可以将PINK1蛋白质有效地用作药物组合物或免疫抑制剂，其能够预防或治疗由各种免疫反应失调引起的自身免疫疾病如关节炎等。

公开(公告)号：US20150196511A1

公开(公告)日：2015-07-16

申请号：US14663235

申请日：2015-03-19

Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Mi-La Cho ,  Seon-Yeong Lee ,  Eun-Ji Yang ,  Hye-Jin Son ,  Eun-Kyung Kim ,  Jun-Geol Ryu

IPC: A61K31/155 ,  A61K39/395

CPC classification number: A61K31/155 ,  A61K38/1793 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to a composition comprising metformin as an active ingredient for preventing or treating inflammatory bowel disease. The metformin compound or the metformin-etanercept (product name: Enbrel) composite according to the present invention may have excellent effects of maintaining the thickness of the small intestine and length of the large intestine normal, inhibiting or decreasing the activity of IL-17 and TNF-a, and promoting or increasing the activity of IFNr, and therefore can be effectively used as a pharmaceutical composition for preventing or treating autoimmune diseases including inflammatory bowel disease.

Abstract translation: 本发明涉及包含二甲双胍作为预防或治疗炎症性肠病的活性成分的组合物。 根据本发明的二甲双胍化合物或二甲双胍 - 依那西普（商品名：恩布雷）复合物可以具有保持小肠厚度和大肠长度正常，抑制或降低IL-17活性和 TNF-α，并且促进或增加IFNr的活性，因此可以有效地用作预防或治疗包括炎性肠病的自身免疫性疾病的药物组合物。

公开(公告)号：US09700531B2

公开(公告)日：2017-07-11

申请号：US14663235

申请日：2015-03-19

Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Mi-La Cho ,  Seon-Yeong Lee ,  Eun-Ji Yang ,  Hye-Jin Son ,  Eun-Kyung Kim ,  Jun-Geol Ryu

IPC: A61K31/155 ,  A61K38/17 ,  A61K39/395 ,  A61P37/02 ,  A61K45/06

CPC classification number: A61K31/155 ,  A61K38/1793 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to a composition comprising metformin as an active ingredient for preventing or treating inflammatory bowel disease. The metformin compound or the metformin-etanercept (product name: Enbrel) composite according to the present invention may have excellent effects of maintaining the thickness of the small intestine and length of the large intestine normal, inhibiting or decreasing the activity of IL-17 and TNF-a, and promoting or increasing the activity of IFNr, and therefore can be effectively used as a pharmaceutical composition for preventing or treating autoimmune diseases including inflammatory bowel disease.

公开(公告)号：US20150238445A1

公开(公告)日：2015-08-27

申请号：US14428920

申请日：2013-09-06

Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Mi-La Cho ,  Seon-Yeong Lee ,  Min-Jung Park ,  Jae-Seon Lee ,  Eun-Ji Yang ,  Eun-Kyung Kim ,  Jun-Geol Ryu ,  Hye-Jin Son

IPC: A61K31/155

CPC classification number: A61K31/155

Abstract: The present invention relates to a composition for preventing or treating immune diseases through the suppression of B cell activity induced by metformin. More particularly, the present invention relates to a composition comprising a metformin compound or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating immune diseases, wherein the composition is characterized by suppression or reduction of B cell activity which is a cause of disease. The present invention can be valuable in the use thereof for various autoimmune diseases as an immunosuppressant which can prevent or treat immune diseases by suppressing or reducing B cell activity and Th17 cell activity, which are causes of disease, or by promoting or increasing regulatory T cell activity.

Abstract translation: 本发明涉及通过抑制二甲双胍诱导的B细胞活性来预防或治疗免疫疾病的组合物。 更具体地，本发明涉及包含二甲双胍化合物或其药学上可接受的盐作为预防或治疗免疫疾病的活性成分的组合物，其中所述组合物的特征在于抑制或降低作为疾病原因的B细胞活性 。 本发明在各种自身免疫性疾病中作为免疫抑制剂的用途是有价值的，该免疫抑制剂可以通过抑制或降低作为疾病原因的B细胞活性和Th17细胞活性或通过促进或增加调节性T细胞来预防或治疗免疫疾病 活动。

公开(公告)号：US20150297676A1

公开(公告)日：2015-10-22

申请号：US14426324

申请日：2013-09-02

Applicant: Catholic University Industry Academic Cooperation Foundation

Inventor： Mi-La CHO ,  Joo-Yeon Jhun ,  Seon-Yeong Lee ,  Yeong-Mi Mun ,  Jun-Geol Ryu ,  Jae-Kyeong Byun ,  Hye-Jin Son ,  Eun-Kyung Kim ,  Eun-Ji Yang ,  Jeong-Hee Jeong

IPC: A61K38/17 ,  G01N33/68 ,  C07K14/47

CPC classification number: A61K38/1709 ,  A61K38/1761 ,  C07K14/47 ,  G01N33/6872 ,  G01N33/6893 ,  G01N2333/4704 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2800/044

Abstract: The present invention relates to a composition comprising GRIM-19 protein as an active ingredient for preventing or treating obesity or lipid-related metabolic diseases. More particularly, the present invention relates to a composition for preventing or treating obesity or lipid-related metabolic diseases wherein the composition comprises GRIM-19 protein as an active ingredient for preventing or treating metabolic diseases caused by immune response disorders or interactions between genetic, metabolic, or environmental complex factors. The GRIM-19 protein according to the present invention exhibits excellent effectiveness not only in reducing lipocytes and total cholesterol content in the body, but also in suppressing the differentiation of cytotoxic Th17 cells that produce and secrete inflammatory cytokines. Also, GRIM-19 has been found to have excellent effectiveness in regulating a STAT3 mediated inflammatory response in an inflammatory environment related to obesity. Thus, the present invention can be used for preparing a treatment agent and a functional food that can effectively treat obesity or lipid-related metabolic diseases.

Abstract translation: 本发明涉及包含GRIM-19蛋白作为预防或治疗肥胖症或与脂质有关的代谢疾病的活性成分的组合物。 更具体地说，本发明涉及用于预防或治疗肥胖症或与脂质有关的代谢性疾病的组合物，其中组合物包含GRIM-19蛋白作为预防或治疗由免疫应答障碍引起的代谢疾病或遗传代谢之间的相互作用的活性成分 ，或环境复杂因素。 根据本发明的GRIM-19蛋白质不仅在体内减少脂肪细胞和总胆固醇含量方面表现出优异的效果，而且在抑制产生和分泌炎性细胞因子的细胞毒性Th17细胞的分化方面表现出优异的效果。 此外，已经发现GRIM-19在与肥胖相关的炎症环境中调节STAT3介导的炎症反应具有优异的有效性。 因此，本发明可用于制备能够有效治疗肥胖症或与脂质有关的代谢疾病的治疗剂和功能性食品。